Risto Erkkola, M.D.t Kerttu Irjala, M.D. Kristiina Ruutiainen, M.D.tll
|
|
- Anabel Gray
- 6 years ago
- Views:
Transcription
1 FRTILITY AND STRILITY Copyright e 199 The American Fertility Society Vol. 58, No.4, October 199 Printed on acid-free paper in U.S.A. Serum androgen and gonadotropin levels decline after progestogeninduced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries Leena Anttila, M.D.t:j: Pertti Koskinen, M.D. Hanna-Leena Kaihola, Ph.D. Risto rkkola, M.D.t Kerttu Irjala, M.D. Kristiina Ruutiainen, M.D.tll University of Turku, Turku, Finland Objective: To examine the effect of short-term progestogen treatment on androgen, gonadotropin, and sex hormone-binding globulin (SHBG) levels in oligomenorrheic women. Design: Comparative study of changes in hormonal parameters in patients with or without ultrasonographically diagnosed polycystic ovarian disease (PCOD). Setting: Open patient clinic of reproductive endocrinology at University Central Hospital of Turku, Finland. Patients: Seventy-five oligomenorrheic women with (n = 51) or without (n = 4) PCOD. Main Outcome Measures: Serum concentrations of testosterone (T), androstenedione (A), dehydroepiandrosterone sulfate, luteinizing hormone (LH), follicle-stimulating hormone (FSH), andshbg. Results: The levels oft, A, LH, and the LH:FSH ratios decreased significantly after oral treatment with medroxyprogesterone acetate (1 mg/d for 1 days) in non-pcod women and in women with PCOD decreasing the frequencies of pathological laboratory findings, in particular elevated levels of LH:FSH ratio and A in PCOD women and of LH:FSH ratio in non-pcod women. The levels oft, A, and LH as well as the LH:FSH ratio were significantly higher in women with PCOD. Obesity was associated with high free androgen indices, low LH:FSH ratios, and low concentrations of LH, A,andSHBG. Conclusions: The serum samples for hormonal analyses used as an aid in diagnosing PCOD should be obtained without pretreatment with progestogen because it masks the biochemical findings of PCOD. Fertil Steril199;58:697-7 Key Words: Polycystic ovarian disease, oligomenorrhea, androgens, gonadotropins, medroxyprogesterone acetate Polycystic ovarian disease (PCOD) is a common cause of amenorrhea, oligomenorrhea, and infertility (1, ). The etiology and pathophysiology of this Received April, 199; revised and accepted June 4, 199. * Supported by grants from the Paulo Foundation, Helsinki, Finland, and the Foundation of the University of Turku, Turku, Finland. t Department of Obstetrics and Gynecology. :j: Reprint requests: Leena Anttila, M.D., Department of Obstetrics and Gynecology, Turku University Central Hospital, Kiinamyllynkatu 4-8, SF-5 Turku, Finland. Central Laboratory, Turku University Central Hospital. II Present address: Department of Obstetrics and Gynecology, The University of Maryland, Baltimore, Maryland. clinical entity are still incompletely understood. Likewise, several diagnostic criteria based on ovarian morphology (-4) or biochemical findings have been presented for PCOD (5-7). In most studies on androgen metabolism in eumenorrheic women, the sampling for hormonal analyses has been carried out in the early follicular phase. In amenorrheic and oligomenorrheic subjects, the results of the hormonal analyses are presumed to become more comparable with the normal early follicular phase values by taking the samples after a progestogen-induced withdrawal bleeding (8). However, it may be questioned whether such treatment would not change the androgen and gonado- Vol. 58, No.4, October 199 Anttila et al. MP A effect on hormones in oligomenorrhea 697
2 tropin status of a patient with menstrual irregularities, thereby masking diagnostic hormonal findings. Cycle-regulating progestagens (e.g., medroxyprogesterone acetate [MPA)) are known to suppress testosterone (T) (9), luteinizing hormone (LH) (9-11), and sex hormone-binding globulin (SHBG) levels (1). The aim of the present study was to investigate the effect of progestogen treatment on the levels of serum androgens, gonadotropins, and SHBG in oligomenorrheic women with or without morphologically diagnosed PCOD. Subjects MATRIALS AND MTHODS The study group consisted of 75 oligomenorrheic women. Oligomenorrhea was defined as menstrual cycles of >6 weeks during the previous 6 to 1 months. Patients with hyperprolactinemia or thyroid dysfunction were excluded. All subjects attending the study bled in response to a progestogen challenge indicating an estrogen ()-primed endometrium. The diagnosis of PCOD was based on ovarian morphology assessed by the same investigator (L.A.) using a 7.5-MHz vaginal ultrasonographic vaginal probe (Combison 31; Kretztechnik, Zipf, Austria) and diagnostic criteria by Adams (3). The body mass index (BMI, weight [kg]/height [m]) was measured. Hair growth was assessed using a modification of the criteria of Ferriman and Gallwey (13). In hirsute and hyperandrogenic women, a dexamethasone suppression test was performed to exclude Cushing's syndrome. Adrenocorticotropin stimulation test was performed when needed to exclude late onset adrenal hyperplasia. Polycystic ovaries fulfilling diagnostic criteria (enlarged ovaries with multiple small subcortical follicles and increased stroma) were found in 51 women. Their age ranged from 14 to 4 years (7.9 ± 5.5 years, mean ± SD) and the BMI from 17 to 56 kg/m (8.8 ± 7.7 kg/m). The remaining 4 women had normal (n = 18) or multicystic (n = 6) ovaries on ultrasound. The age of the non-pcod women ranged from 19 to 4 years ( years) and the BMI from 18 to 48 kg/m (8.4 ± 9. kg/m). Thirty-one women with and 1 without PCOD were obese (BMI > 5 kg/m). Hirsutism (total score> 9) were found in 11 women with PCOD. None of the women without PCOD were hirsute. Hormone Sampling The blood samples were collected after an overnight fast between 7 and 9 A.M. The first samples were taken during oligomenorrhea. The sampling was repeated after an MPA-induced (MPA 1 mg/d for 1 days) withdrawal bleeding (days 3 to 7 after the onset of induced menstrual flow). Hormone and SHBG Assays Serum T and androstenedione (A) were measured with in-house radioimmunoassays (RIAs) as described previously (14). Dehydroepiandrosterone sulfate (DHAS) was measured with an RIA (151_ DHAS RIA kit; Baxter Dade AG, Dudingen, Germany). Luteinizing hormone and follicle-stimulating hormone (FSH) were measured with time-resolved immunofluorometric assays (Delfia; Wallac Oy, Turku, Finland). Sex hormone-binding globulin was determined with a ligand-binding assay (14). The free androgen index was calculated as the quotient T (nmoljl)/shbg (nmoljl) X 1,. The early follicular phase reference intervals for all the analytes were determined in 4 healthy female volunteers (14). Statistical Methods Paired differences were evaluated with the paired t-test. The effects of PCOD and obesity in the entire study group and hirsutism in the subgroup with PCOD on the hormone and SHBG levels were assessed with ANCOV A. The changes in the distribution were analyzed with McNemar's Xtest. RSULTS The serum concentrations of T, A, and LH as well as the LH:FSH ratios decreased significantly after treatment with MPA in women with PCOD as well as in non-pcod women (Table 1, Fig. 1). The levels ofdhas and the free androgen indices decreased significantly only in PCOD women (Table 1, Fig. 1). The levels of T, A, and LH as well as the LH: FSH ratios and the free androgen indices were higher in women with PCOD than in non-pcod women both in the oligomenorrheic state and after MPA-induced bleeding (Table 1). The PCOD and non-pcod women did not differ with respect to serum DHAS concentrations (Table 1). Figure shows the distributions of the women according to normal (outside the appropriate circle) or elevated (inside the circle) LH:FSH ratios, free androgen indices, and A concentrations in oligomenorrhea and after MPA-induced bleeding. The overlaping areas present those with more than 698 Anttila et at. MPA effect on hormones in oligomenorrhea Fertility and Sterility
3 Table 1 Gonadotropins, Androgens, and SHBG in the Study Groups* Cycle phase PCODwomen Probabilityt Non-PCOD LH (lull) Oligomenorrhea 1.8 ± 5.5 (1. to 9):1: < ± 5.5 (1 to 18) After MPA 7.4 ± 4.5 (1.4 to 8):1: < ±.8 (1.4 to 1) LH:FSH ratio Oligomenorrhea.4 ± 1.1 (.9 to 5.6):1: < ± 1.1 (.3 to 3.8) After MPA 1.7 ±.8 (.4 to 4.):1: < ±.6 (.3 to.1) T (nmol/l) Oligomenorrhea 3.1 ±.9 (1.9 to 5.9):1: <.1. ±.4 (1.5 to 3.3) After MPA.5 ±.7 (1.3 to 4.7):1: < ±.3 (1. to.4) SHBG (nmol/l) Oligomenorrhea 35. ±.5 (7 to 91) II NS1f 4. ±.6 (18 to 94) II After MPA 34.8 ±.8 (6 to 11) II NS 38.4 ± 19. (19 to 88) II Free androgen Oligomenorrhea 1Z ±83 (35 to 475):1: <.1 56 ± 4 ( to 111) II index After MPA 98 ± 64 (6 to 3):1: <.1 55 ± 4 (19 to 1) II A (nmol/l) Oligomenorrhea 13.3 ± 3.9 (7. to.6):1: < ±.5 (3.8 to 15.9) After MPA 1.3 ± 3.4 (5.1 to.1):1: < ± 1.4 (4.9 to 1.8) DHAS Oligomenorrhea 7. ± 3.4 (. to 16.3) NS 5.8 ±.9 (1.7 to 1.5) II (ltmol/l) After MPA 7.6 ± 4.1 (. to 16.6) NS 6. ±.3 (1.6 to 9.7) II * Values are means ± SD with ranges in parentheses. t The difference between PCOD and non-pcod women. :I: The difference between the results obtained during oligomenorrhea and after MPA-induced bleeding, P <.1. The difference between the results obtained during oligomenorrhea and after MPA-induced bleeding, P <.1. II The difference between the results obtained during oligomenorrhea and after MPA-induced bleeding is not significant. 1f NS, not significant. one abnormal finding. Treatment with MP A decreased the frequency of pathological laboratory findings, in particular elevated levels of LH:FSH ratio (from 66% to 38%, P <.1) and A (from 66% to 34%, P <.1) in PCOD women and elevated levels of LH:FSH ratio (from 57% to 13%, P <.5) in non-pcod women. Seventy-seven percent of PCOD women had a combination of more than one pathological finding. The frequency decreased to 51 % after MP A in the PCOD group (P <.1). Among the non-pcod group, elevated LH:FSH ratio together with elevated free androgen index was found in 4 % of subjects in the non PCOD group during oligomenorrhea. Only one of the non-pcod women had high A during amenorrhea (Fig. 1). Free androgen index was elevated in 83% of PCOD patients and 59% of non-pcod patients, in whom mainly obese subjects had elevated free androgen indicies (Fig. ). No significant difference was found in BMI between PCOD and non-pcod women. Obesity was associated with high levels of free androgen index (P <.1, Fig. 3) and low levels of LH (P <.1), LH:FSH ratio (P <.1, Fig. 3), A (P <.5, Fig. 3), and SHBG (P <.1) in oligomenorrheic state. The levels of SHBG were significantly lower (9.7 ± 18.3 nmoljl versus 4. ± 1.1 nmoljl, P <.5) and the levels of free androgen index significantly higher (13.8 ± 73.9 versus 89.7 ± 45., P <.5) in hirsute than in nonhirsute PCOD women. No significant difference was found in BMI between the hirsute and nonhirsute PCOD groups. DISCUSSION We have previously shown that the timing of the hormone sampling is important when exploring the androgen and particularly the gonadotropin status in regularly menstruating women (14). During a normal menstrual cycle, T and SHBG values are greater in the luteal phase, but despite the cyclic variation, serum androgen concentrations and especially free androgen index are confined within narrow limits (14). However, the levels of the LH: FSH ratio as measured by novel fluoroimmunoassays vary more in the luteal phase (range.3 to 3.5; coefficient variation [CV] 6%) than in the early follicular phase (range. to 1.7; CV 3%) (14). Identifying excessive androgen production resulting in hyperandrogenism and altered gonadotropin secretion resulting in a high LH:FSH ratio has widely been used in the biochemical diagnosis of PCOD (5-7). To get adequate information of gonadotropin and androgen status is problematic in patients with occasional ovulations and/or periods, as often found in PCOD patients. It has been recommended that the hormone samples should be taken in amenorrheic and oligomenorrheic patients after a progestogen-induced bleeding (8). This view relies on the assumption that progestogen administration would mimic the luteal phase, rendering the results more comparable with the early follicular phase values. In this study, we found highly significant declines in the levels of LH and androgens after a short-term Vol. 58, No.4, October 199 Anttila et al. MPA effect on hormones in oligomenorrhea 699
4 ... % II) u. ::: %...J '" ::: ". 15 " e 1 «" 5. II) 5, ::: 4 ". Cl 3 :I: '" II) ::: ". M M M M M M ob le.n ob.,. I n obi I n hinute "onhinut. nonhirlute pedd non-pcoo M M M M M M ob... I.,n ob... I.. n ob.,. le.n hinut. nonhinut. "orhinut. pedd non-pcod Ssil l; '" M M M M M M obese I n obese lean obese I n hirsute nonhinut. "onhinut. peed non-pedd Figure 1 Serum LH:FSH ratios, free androgen indices, and A concentrations in women with PCOD and non-pcod women before () and after (M) MPA-induced withdrawal bleeding. Rectangles indicate the reference intervals. ment suppresses T (9), LH (9), and SHBG (1) levels. Homburg and his co-workers (1) found an intramuscular (1M) short-term MPA (5 mgjd for 5 days) to markedly influence the gonadotropin release. Furthermore, 7 of 1 clomiphene citrate (CC) resistant PCOD women responded to CC with ovulation after such pretreatment (1). Petsos et al. (11) found MPA treatment (5 mg two times daily for 14 days) to suppress LH and FSH levels. In this work, even a short-term MPA treatment masked the biochemical findings of PCOD in several patients (Fig. ). The rather long half-life ofmpa (4 to 5 hours) may explain the changes in hormonal levels even though the samples for endocrinological evaluation were collected approximately 6 to 1 days after the last MP A dose. Despite the mean levels of LH, the LH:FSH ratios' and all other androgen levels except DHAS were significantly higher in the PCOD group, we found considerable heterogeneity of biochemical findings within PCOD patients (Fig. ). This finding is in accordance with the current concept of the heterogeneous etiology of PCOD. Fox et al. () have recently suggested that a positive progestogen challenge test (5 mg oral MPA for 5 days) alone can predict PCOD in oligoamenorrheic subjects. Moreover, they found that the combination of LH and free androgen index was the best biochemical test to predict PCOD in oligoamenorrheic subjects. In this study, all subjects had a positive progestogen challenge test, indicating an -primed endometrium. Within the non-pcod group, 57% of LH/FSH In oligomenorrhea lhffsh Androstenedione LH/FSH In oligomenorrhea lh/fsh Androstenedione Androstenedione oral treatment with MPA (Table 1, Fig. 1). The abnormal gonadotropin secretion in the PCOD patients is presumed to be reversible because of chronic deprivation of progesterone (P) (15). Progesterone acts at hypothalamic levels, decreasing LH pulse frequency (16). Similarly, vaginal P supplementation decreases LH pulse frequency in anovulatory PCOD women (17). Furthermore, in PCOD women ovulation is followed by a temporary normalization of the LH:FSH ratio (18, 19). Long-term MPA-treat- Afler MPA-induced Withdrawal bleeding PCOD After MPA-Induced Withdrawal bleeding non-pcod Figure The distribution (%) ofpcod and non-pcod women according to elevated (inside the appropriate circle) or normal (outside the circle) levels of serum A (upper limit of the reference interval 11 nmol/l), free androgen index (T/SHBG X 1,, upper limit ofthe reference interval 55) and LH:FSH ratio (upper limit of the reference intervall. 7). Percentages of subjects are shown in the states of oligomenorrhea and after MPA-induced withdrawal bleeding. The overlaping areas present those women with more than one pathological finding. 7 Anttila et a1. MPA effect on hormones in oligomenorrhea Fertility and Sterility
5 s : I 4 en..s l<i C) 3 m I 3 o o II!::J en I... -' " (; ODD l1li.,.s en I- 1 c9 c7l BMI (kg/m) c BMI (kg/) o 6 5.s., c. "., c!! " C «CD en o 1 o o cg :. db --.. '""- c9c J ClIO o o cji CO 6 Figure 3 Relationship between BMI and LH:FSH ratios, free androgen index (T/SHBG X 1,), and A in hirsute (_) and nonhirsute women (D) with PCOD and non-pcod oligomenorrheic women (). the women had elevated LH:FSH ratio during oligomenorrhea; thus the elevation of LH is not a pathognomonic feature of PCOD. Furthermore, free androgen index was elevated in 59% of non-pcod patients and, in accordance with earlier reports (1, ), elevated free androgen index was associated with obesity within non-pcod patients (Figs. 1 and 3). The combination of elevated free androgen index together with high LH:FSH ratio was found in 4% of non-pcod patients. Within PCOD women, elevated levels of free androgen index were found in both obese and lean subjects (together 83%). Highest free androgen indexes and lowest SHGB values were found in hirsute PCOD women. Among the PCOD women, 77% had a combination of more than one pathological finding. Interestingly, elevated A concentration, presumably reflecting the ovarian overproduction, was found only in the PCOD group (66%). We recently have demonstrated that obesity is related to low/normal bioactive LH concentrations within PCOD women (3). In this study, we measured the gonadotropins with highly sensitive fluoroimmunoassays, which have a good correlation with the bioassay (4). Our results concerning the association of obesity to lower LH concentrations within PCOD women is in agreement with that previously stated by Laatikainen and his co-workers (5), who found normal LH levels in massively obese PCOD patients. Furthermore, obesity has significant effect on free androgen indexes, LH:FSH ratios, and A concentrations. Thus, the common practice to compare the hormonal findings simply between lean (BMI < 5) and obese (BMI > 5) subjects may obscure the effects of varying degrees of obesity. The ultrasonographically diagnosed PCOD group showed considerable heterogeneity as concerning the biochemical findings. Which of the biochemical changes is the most efficient diagnostic analyte for the disease obviously depends on the pathogenetic mechanism that primarily prevails behind each individual case of PCOD. In conclusion, the pretreatment with MP A lowered significantly androgen and LH levels both in PCOD and non-pcod patients. Thus the samples for hormonal analyses used as an aid in diagnosing PCOD should be obtained in native state because progestagen treatment masks biochemical findings of PCOD. Acknowledgments. We are indebted to Katariina Korkeila, M.D., and Jaana Lepisto, M.D., for their help in collecting the data. RFRNCS 1. Hull MGR. pidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol ndocrinol 1987;1: Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and hirsutism. Br Med J 1986;93: Adams J, Polson DW, Abdul Wahid N, Morris DV, Franks S, Mason HD, et al. Multifollicular ovaries: clinical and endocrine features and responses to pulsatile gonadotropin releasing hormone. Lancet 1985;1: Ardaens Y, Robert Y, Lemaitre L, Fossati P, Dewailly D. Polycystic ovarian disease: contributions of vaginal endosonography and reassessment of ultrasonic diagnosis. Fertil SteriI1991;55: Yen SSC. The polycystic ovary syndrome. Clin ndocrinol (Oxf) 198;1: Rebar R, Judd HL, Yen SSC, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1979;57: Lobo RA, Grager L, Gobelsmann U, Mishell DR Jr. levations of unbound serum estradiol as a possible mechanism Vol. 58, No.4, October 199 Anttila et al. MPA effect on hormones in oligomenorrhea 71
6 for inappropriate gonadotropin secretion in women with PCOD. J Clin ndocrinol Metab 1981;5: Heineman MJ, Thomas CMG, Doesburg WH, Rolland R. Hormonal characteristics of women with clinical features of the polycystic ovary syndrome. ur J Obstet Gynecol Reprod Bioi 1984;17: Wortsman J, Singh KB, Murphy J. vidence for the hypothalamic origin of the polycystic ovary syndrome. Obstet Gynecol 1981;58: Homburg R, Weissglas L, Goldman J. Improved treatment for anovulation in polycystic ovarian disease utilizing the effect of progesterone on the inappropriate gonadotropin release and clomiphene response. Hum Reprod 1988;3: Petsos P, Ratcliffe WA, Anderson DC. ffects of medroxyprogesterone acetate in women with polycystic ovary syndrome. Clin ndocrinol (OxO 1986;5: Wortsman J, Khan MS, Rosner W. Suppression of testosterone-estradiol binding globulin by medroxyprogesterone acetate in polycystic ovary syndrome. Obstet GynecoI1986;67: Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin ndocrinol Metab 1961;1: Anttila L, Koskinen P, Irjala K, Kaihola H-L. Reference intervals for serum sex steroids and gonadotropins in regularly menstruating women. Acta Obstet Gynecol Scand 1991;7: Berga SL, Yen SSC. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. Clin ndocrinol (OxO 1989;3: Soules MR, Steiner RA, Clifton DK, Cohen NL, Aksel S, Bremner W J. Progesterone modulation of pulsatile luteinizing secretion in normal women. J Clin ndocrinol Metab 1984;58: Bruckler HM, Phillips S, Cameron IT, Healy DL. Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome. J Clin ndocrinol Metab 1988;67: den JA, Place J, Carter GD, Alaghand-Zadeh J, Pawson W. The role of chronic anovulation in the polycystic ovary syndrome: normalization of sex-hormone-binding globulin levels after clomifen-induced ovulation. Clin ndocrinol (OxO 1989;3: Blankstein J, Rabinovici J, Goldenberg M, Shaley J, Mehta A, Serr DM, et al. Changing pituitary reactivity to folliclestimulating hormone and luteinizing hormone-releasing hormone after inducted ovulatory cycles and after anovulation in patients with polycystic ovarian disease. J Clin ndocrinol Metab 1987;65: Fox R, Corrigan, Thomas PA, Hull MGR. The diagnosis of polycystic ovaries in women with oligo-amenorrhea: predictive power of endocrine tests. Clin ndocrinol (OxO 1991;34: Hosseinian AH, Kim MH, Rosenfield RL. Obesity and oligomenorrhea are associated with hyperandrogenism independent of hirsutism. J Clin ndocrinol Metab 1976;4: Grenman S, Riinnemaa T, Irjala K, Kaihola H-L, Griinroos M. Sex steroid, gonadotropin, cortisol and prolactin levels in healthy, massively obese women: correlation with abdominal fat cell size and effect of weight reduction. J Clin ndocrinol Metab 1986;63: Anttila L, Ding Y -Q, Ruutiainen K, rkkola R, Irjala K, Huhtaniemi 1. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease. Fertil Steril 1991;55: Jaakkola T, Ding Q-Y, Kellokumpu-Lehtinen P, Valavaara R, Martikainen H, Tapanainen J, et al. The ratios of serum bioactive/immunoactive luteinizing hormone and folliclestimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation of highly sensitive immunometric assay. J Clin ndocrinol Metab 199;7: Laatikainen T, Tulenheimo A, Andersson B, Kiirkkiiinen J. Obesity, serum steroid levels and pulsatile gonadotropin secretion in polycystic ovarian disease. ur J Obstet Gynecol Reprod Bioi 1983;15: Anttila et al. MPA effect on Iwrmones in oligomenorrhea Fertility and Sterility
Influence of body mass index and age on the grade of hair growth in hirsute women of reproductive ages*
FERTILITY AND STERILITY Copyright 1988 The American Fertility Society Vol. 50, No. 2, August 1988 Printed in U.S.A. Influence of body mass index and age on the grade of hair growth in hirsute women of
More informationDaily blood hormone levels related to the luteinizing hormone surge in anovulatory cycles
FRTILITY AND STRILITY Copyright 1983 The American Fertility Society Printed in U.8A. Daily blood hormone levels related to the luteinizing hormone surge in anovulatory cycles Chung H. Wu, M.D. * F. Susan
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationThe prevalence of polycystic ovaries in healthy women
Acta Obstet Gynecol Scand 1999; 78: 137 141 Copyright C Acta Obstet Gynecol Scand 1999 Printed in Denmark all rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationEndocrinologic features of oligomenorrheic adolescent girls*
FERTILITY AND STERILITY Copyright 1986 The American Fertility Society Printed in U.SA. Endocrinologic features of oligomenorrheic adolescent girls* Rita Siegberg, M.D. t Carl Gustaf Nilsson, M.D. Ulf-Hakan
More informationTreatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy*
Gynecology-endocrinology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U S. A. Treatment of hirsutism with a gonadotropin-releasing hormone agonist
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationPCOS and Obesity DUB is better treated by OCPs
PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One
More informationDiagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome
Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationOccult hyperprolactinemia in infertile women
FRTILITY AND STRILITY Copyright e 1993 The American Fertility Society Printed on acidfree paper in U. S. A. Occult hyperprolactinemia in infertile women Kunio Asukai MD Tsuguo Uemura M.D Hiroshi Minaguchi
More informationEFFECT OF DEXAMETHASONE AND CLOMIPHENE CITRATE ON PERIPHERAL STEROID LEVELS AND OV ARIAN FUNCTION IN A HIRSUTE AMENORRHEIC PATIENT*
FERTILITY AND STERILITY Copyright 1976 The American Fertility Society Vol. 27, No, 6, June 1976 Printed in UB.A. EFFECT OF DEXAMETHASONE AND CLOMIPHENE CITRATE ON PERIPHERAL STEROID LEVELS AND OV ARIAN
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationX/99/$03.00/0 Vol. 84, No. 5 The Journal of Clinical Endocrinology & Metabolism Copyright 1999 by The Endocrine Society
0021-972X/99/$03.00/0 Vol. 84, No. 5 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society A New Contributing Factor to Polycystic Ovary Syndrome:
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationAmenorrhoea: polycystic ovary syndrome
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationEndocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound
Human Reproduction vol.12 no.5 pp. 905 909, 1997 Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound E.Carmina 1, L.Wong 2, L.Chang 2, R.J.Paulson 2, disturbance of the IGF/IGFBP-l
More informationReproductive outcome in women with body weight disturbances
Reproductive outcome in women with body weight disturbances Zeev Shoham M.D. Dep. Of OB/GYN Kaplan Hospital, Rehovot, Israel Weight Status BMI (kg/m 2 ) Underweight
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationOptimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome*
FERTILITY AND STERILITY Vol. 65, No, 3, March 1996 Copyright (i"; 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Optimal use of hormone determinations in the biochemical
More informationProf.Dr. Nabil Lymon Head of Internal Medicine Department
By Prof.Dr. Nabil Lymon Head of Internal Medicine Department Definitions: Hirsutism: Is the presence of terminal hair in androgendependent sites where hair does not normally grow in women. This hair growth
More informationMetfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study
Original Research Article Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study Allanki Suneetha Devi 1, Jalem Anuradha 2* 1 Associate Professor, Department of Obstetrics and Gynecology,
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More informationCobbold Laboratories, University College and Middlesex School of Medicine, Middlesex Hospital, London, United Kingdom
FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Polycystic ovaries in patients with hypogonadotropic hypogonadism: similarity of ovarian response
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More informationMetformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 69, NO. 4, APRIL 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Metformin therapy improves
More informationRelation of luteinizing hormone levels to body mass index in premenopausal women
FERTILITY AND STERILITY VOL. 69, NO. 3, MARCH 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Relation of luteinizing
More informationApproach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD
Approach to ovulation induction and superovulation in women with a history of infertility Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the
More informationThe Effect of Vitamin D Replacement Therapy on Serum Leptin and Follicular Growth Pattern in Women with Clomiphene Citrate Resistant Polycystic Ovary
Med. J. Cairo Univ., Vol. 84, No. 2, June: 85-89, 2016 www.medicaljournalofcairouniversity.net The Effect of Vitamin D Replacement Therapy on Serum Leptin and Follicular Growth Pattern in Women with Clomiphene
More informationMetformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study
The Journal of Obstetrics and Gynecology of India (September-October 2012) 62(5):551 556 DOI 10.1007/s13224-012-0183-3 ORIGINAL ARTICLE Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative
More informationThe prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria
Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationClinical Profile Polycystic Ovarian Syndrome Cases
ORIGINAL RESEARCH www.ijcmr.com - 100 Cases Himabindu Sangabathula 1, Neelima Varaganti 1 ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is most common endocrine disorders of reproductive age
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationTHE RELATION BETWEEN PLASMA TESTOSTERONE LEVELS AND THE LENGTHS OF PHASES OF THE MENSTRUAL CYCLE*
FERTILITY AND STERILITY Copyright 1979 The American Fertility Society Vol. 32, No.4, October 1979 Printed in U.s.A. THE RELATION BETWEEN PLASMA TESTOSTERONE LEVELS AND THE LENGTHS OF PHASES OF THE MENSTRUAL
More informationHannele Hohtari, M_D.t Katariina Salminen-Lappalainen, M.Sc.:j: Timo Laatikainen, M.D.:j:
FRTILITY AND STRILITY Copyright e 1991 The American Fertility Society Vol. 55, No.2, February 1991 Printed on acid-free paper in U.S.A. Response of plasma endorphins, corticotropin, cortisol, and luteinizing
More informationKey words: laparoscopic ovarian multiple punch resection, laparoscopic ovarian electrocautery, infertility,
Key words: laparoscopic ovarian multiple punch resection, laparoscopic ovarian electrocautery, infertility, polycystic ovarian syndrome, clomiphene citrate 1) Insler V, Zakut H, Serr M. Cycle pattern
More informationThe importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility
FERTILITY AND STERILITY Copyright 0 1988 The American Fertility Society Printed in U.S.A. The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in
More informationPOLYCYSTIC OVARY SYNDROME INA S. IRABON,MD, FPOGS,FPSRM,FPSGE OBSTETRICS AND GYNECOLOGY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY
POLYCYSTIC OVARY SYNDROME INA S. IRABON,MD, FPOGS,FPSRM,FPSGE OBSTETRICS AND GYNECOLOGY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY TO DOWNLOAD LECTURE DECK MAIN REFERENCE Comprehensive Gynecology 7 th
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Kathleen Colleran, MD Professor of Medicine University of New Mexico HSC Presented for COMM-TC May 4, 2012 Objectives Understand the pathophysiology of PCOS Understand how to
More informationReproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
More informationMETABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline for the Investigation and Management of Polycystic Ovary Syndrome Author: Contact Name and Job Title
More informationClinical Study and Outcome of Polycystic Ovarian Syndrome
NJOG 2011 May-June; 6 (1): 22-27 Clinical Study and Outcome of Polycystic Ovarian Syndrome Gayatri Linganagouda Patil 1, Geeta Hosanemati 1, L.S.Patil 2, Vijayanath.V 3, Venkatesh M Patil 4, Rajeshwari.
More informationSelection criteria of normal controls to predict reliable cut-off values of various endocrine parameters in infertility
J Obstet Gynecol India Vol. 55, No. 1 : January/February 2005 Pg 72-76 ORIGINAL ARTICLE The Journal of Obstetrics and Gynecology of India Selection criteria of normal controls to predict reliable cut-off
More information16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA
16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA Katie O Sullivan, MD Adult/Pediatric Endocrinology Fellow University of Chicago ENDORAMA Thursday, September 4th, 2014 Disclosures No financial interests. Will
More informationCASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?
CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,
More informationFrank Gonzalez, M.D.,* Lillie Chang, M.D., Theresa Horab, R.N.,* Frank Z. Stanczyk, Ph.D., Kent Crickard, M.D.,* and Rogerio A. Lobo, M.D.
FERTILITY AND STERILITY VOL. 71, NO. 3, MARCH 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Adrenal dynamic responses
More informationUterus & Ovary 2015; 2: e904. doi: /uo.904; 2015 by Ahmed M Maged, et al.
RESEARCH ARTICLE Phytoestrogens as an alternative to estradiol in reversing the antiestrogenic effect of clomid on endometrium in ovulation induction in cases of polycystic ovarian syndrome (PCOS) Ahmed
More informationPolycystic Ovary Syndrome
What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular
More informationThe contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome
Human Reproduction vol.14 no.2 pp.307 311, 1999 The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome E.Carmina 1, F.Gonzalez 2, A.Vidali
More informationProlactin modulates peripheral androgen metabolism*
FERTILITY AND STERILITY Copyright 1986 The American Fertility Society Printed in USA, Prolactin modulates peripheral androgen metabolism* Paulo Serafini, M,D, t Rogerio A, Lobo, M,D,:j: Department of Obstetrics
More informationWEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY
ENDOCRINE REGULATIONS, VOL. 40, 119-123, 2006 119 WEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY J. VRBIKOVA, K. DVORAKOVA, M. HILL, L. STARKA Institute
More informationNature and Science 2017;15(8)
Prognostic Value of Day 3 Luteinising Hormone (LH) in the prediction of Ovarian Response in Patients with Polycystic Ovary syndrome Mohammed Samir Fouad 1 ; Mohammed Said El-Shorbagy 2, Mohammed Mohammed
More informationPoly cystic ovary syndrome: the spectrum of the disorder in 1741 patients
Human Reproduction vol.10 no.8 pp.21o7-2111, 1995 Poly cystic ovary syndrome: the spectrum of the disorder in 1741 patients Adam H. Balen 1, Gerry S.Conway, Gregory Kaltsas, Kitirak Techatraisak, Patrick
More informationNazanin Farshchian, Siavash Teimuri Nezhad, and Parisa Bahrami Kamangar RESEARCH ABSTRACT. What this study adds: Background
The combination of letrozole and metformin has a better therapeutic effect on uterine and ovarian arteries in PCOS patients than the combination of clomiphene citrate and metformin Nazanin Farshchian,
More informationInfertility for the Primary Care Provider
Infertility for the Primary Care Provider David A. Forstein, DO FACOOG Clinical Associate Professor Obstetrics and Gynecology University of South Carolina School of Medicine Greenville Disclosure I have
More informationEbtisam S. S. Al-Mizyen, M.B. Ch.B., M. Phil. * Jurgis G. Grudzinskas, M.D., F.R.C.O.G., F.R.A.C.O.G., B.Sc., M.B., B.S.
Middle East Fertility Society Journal Vol. 12, No. 3, 27 Copyright Middle East Fertility Society Ultrasonographic observations following unilateral and bilateral laparoscopic ovarian diathermy in infertile
More informationUltrasonographic patterns of polycystic ovaries: color Doppler and hormonal correlations
Ultrasound Obstet Gynecol 1998;11:332 336 Ultrasonographic patterns of polycystic ovaries: color Doppler and hormonal correlations C. Battaglia, P. G. Artini, M. Salvatori, S. Giulini, F. Petraglia, N.
More informationPrevalence of polycystic ovarian syndrome in the Buraimi region of Oman
Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine
More informationCase. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?
Hirsutism Case 24 year old female presented to your office complaining of excess hair growth on her face and abdomen Questions? Started around puberty with gradual progression Irregular menstrual cycle
More informationIdiopathic hirsutism: an uncommon cause of hirsutism in Alabama
FERTILITY AND STERILITY VOL. 70, NO. 2, AUGUST 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Idiopathic hirsutism:
More informationAbnormal Uterine Bleeding Case Studies
Case Study 1 Abnormal Uterine Bleeding Case Studies Abigail, a 24 year old female, presents to your office complaining that her menstrual cycles have become a problem. They are now lasting 6 7 days instead
More informationGynecology-endocrinology
Gynecology-endocrinology FERTILITY AND STERILITY Copyright (fj 1991 The American Fertility Society Vol. 55, No, 5, May 1991 Printed on acid-free paper in U.S.A. Serum androsterone conjugates differentiate
More informationWHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED
WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED Ricardo Azziz, M.D., M.P.H., M.B.A. Chief Officer of Academic Health & Hospital Affairs State University of New York (SUNY)
More information2-Hypertrichosis:- Hypertrichosis is the
Hirsutism And Virilization Hirsutism:- Is the development of androgen-dependent dependent terminal body hair in a woman in places in which terminal hair is normally not found, terminal body hairs are the
More informationGONADAL FUNCTION: An Overview
GONADAL FUNCTION: An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences Clinical Biochemistry BMLS III & BDS IV VJ Temple 1 What are the Steroid hormones?
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24875
More informationInternational Journal of Advanced Research in Biological Sciences ISSN : Research Article
International Journal of Advanced Research in Biological Sciences ISSN : 2348-8069 www.ijarbs.com Research Article Tamoxifen or Drospirenone and Ethinyl Estradiol: which is the first choice for infertile
More informationPrevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study
Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study Mousa Mohsen Ali* Wasan Ghazi* HayderAamerAbboud^ *Kerbala University, College of Medicine, Gynecology
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69 Effect of Metformin Only versus Effect of Metformin and Corticosteroids after Laparoscopic Ovarian Drilling on Ovulation
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationEFFECT OF WEIGHT LOSS ON OVARIAN AND ADRENAL ANDROGEN SENSITIVITY. Department OB/GYN. EVMA Norfolk, Va Telephone: (804)
This study predates but predicts the use of glucophage, exercise and diet for the treatment of PCO. EFFECT OF WEIGHT LOSS ON OVARIAN AND ADRENAL ANDROGEN SENSITIVITY Principal Investigator: Hofheimer Hall
More informationPulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment
Human Reproduction vol.12 no.6 pp.1156 1164, 1997 Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment Anthony P.Cheung 1,3,
More informationDifferences in ovarian stimulation in human menopausal gonadotropin treated woman may be related to follicle-stimulating hormone accumulation*
FRTILITY AND STRILITY Copyright 0 1986 The American Fertility Society Vol. 46, No.4, October 1986 Printed in U.8A. Differences in ovarian stimulation in human menopausal gonadotropin treated woman may
More informationGrowth hormone response to clonidine in anovulatory infertile women resistant to clomiphene citrate stimulation
FERTILITY AND STERILITY VOL. 73, NO. 1, JANUARY 2000 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Growth hormone response
More informationROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME
ORIGINAL ARTICLE ROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME 1 2 3 Samdana Wahab, Farnaz, Rukhsana Karim ABSTRACT Objective: To assess the role of Metformin in Polycystic ovarian syndrome (PCOS).
More informationNew PCOS guidelines: What s relevant to general practice
New PCOS guidelines: What s relevant to general practice Dr Michael Costello Fertility Specialist IVF Australia UNSW Royal Hospital for Women Sydney How do we know if something is new? Louvre Museum, Paris
More informationPCOS. Reproductive Gynaecology and Infertility. Dr.Renda Bouzayen MD.FRCSC GREI,OBGYN Dalhousie University
Reproductive Gynaecology and Infertility PCOS Dr.Renda Bouzayen MD.FRCSC GREI,OBGYN Dalhousie University Dr.Hussein Sabban MD. FRCSC PGY6 GREI Dalhousie University Disclosure No conflict of interest Pilot
More informationSalivary Versus Serum Approaches in Assessment of Biochemical Hyperandrogenemia
Original Article Salivary Versus Serum Approaches in Assessment of Biochemical Hyperandrogenemia Mohamed Nabih El Gharib, Sahar Mohey El Din Hazaa 1 Departments of Obstetrics and Gynecology, and 1 Clinical
More informationPolycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis?
Polycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis? Poster No.: C-1238 Congress: ECR 2010 Type: Scientific Exhibit Topic: Genitourinary Authors: G. Tony, N. V. Gurjar,
More informationPolycystic ovary syndrome
Jon Havelock, MD, FRCSC Polycystic ovary syndrome Therapy for this reproductive and metabolic disorder remains focused on managing symptoms, including infertility caused by anovulation, and reducing long-term
More informationlactotrophs 120 min- FSH 60 min- LH Hypothalamus GnRH pituitary Estradiol +/- Progesterone _ FSH L H Ovary Uterus Ovulation Antral follicle >2mm
lactotrophs Hypothalamus GnRH 120 min- 60 min- LH Progesterone _ pituitary L H + Ovary + Estradiol +/- Uterus Antral follicle >2mm Ovulation Preovulatory follicles atresia Follicular phase Luteal phase
More informationValidation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D., a Bart C. J. M. Fauser, M.D., Ph.D., b Joop S. E. Laven,
More information12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND
Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND 7% of all women 18-45 Obesity 1/3 of all US women Incidence of PCOS is increasing with increase obesity Obesity Irregular
More informationJournal of American Science 2013;9(12)
Early Clomiphene Citrate for Induction of Ovulation in Women with Polycystic Ovary Syndrome a randomized controlled trial Elguindy A. 1, Hussein M. 1 * and El-Shamy R 2 1 Department of Obstetrics and Gynecology,
More informationusually, but not always, enlarged.' These are features that can be identified using high resolution ultrasonography of the ovaries.
BRITISH MEDICAL JOURNAL VOLUME 293 9 AUGUST 1986 355 PAPERS AND SHORT REPORTS Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism J ADAMS, D W POLSON, S FRANKS Abstract
More information13 th Annual Women s Health Day PCOS. Saturday 02/09/2017 Dr Mathias Epee-Bekima O&G Consultant KEMH
13 th Annual Women s Health Day PCOS Saturday 02/09/2017 Dr Mathias Epee-Bekima O&G Consultant KEMH Learning objectives Perform the appropriate investigations in women where there is a clinical suspicion
More information